Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Purple Biotech (PPBT) Share-based Compensation (IS) (2017 - 2025)

Purple Biotech has reported Share-based Compensation (IS) over the past 6 years, most recently at -$240000.0 for Q4 2022.

  • Quarterly Share-based Compensation (IS) fell 178.69% to -$240000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2022, down 35.98% year-over-year, with the annual reading at $309000.0 for FY2025, 46.91% down from the prior year.
  • Share-based Compensation (IS) was -$240000.0 for Q4 2022 at Purple Biotech, down from $707000.0 in the prior quarter.
  • Over five years, Share-based Compensation (IS) peaked at $1.9 million in Q4 2020 and troughed at -$240000.0 in Q4 2022.
  • The 5-year median for Share-based Compensation (IS) is $557000.0 (2022), against an average of $567636.4.
  • Year-over-year, Share-based Compensation (IS) soared 380.12% in 2019 and then plummeted 178.69% in 2022.
  • A 5-year view of Share-based Compensation (IS) shows it stood at $161000.0 in 2018, then skyrocketed by 380.12% to $773000.0 in 2019, then surged by 145.15% to $1.9 million in 2020, then tumbled by 83.91% to $305000.0 in 2021, then plummeted by 178.69% to -$240000.0 in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Share-based Compensation (IS) are -$240000.0 (Q4 2022), $707000.0 (Q3 2022), and $557000.0 (Q2 2022).